TY - JOUR
T1 - Phase II trial of menogaril in non-Hodgkin's lymphomas
T2 - A southwest oncology group trial
AU - Moore, Dennis F.
AU - Brown, Thomas D.
AU - LeBlanc, Michael
AU - Dahlberg, Steve
AU - Miller, Thomas P.
AU - McClure, Suzanne
AU - Fisher, Richard I.
N1 - Funding Information:
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA13612, CA46282, CA42777, CA32734, CA58416, CA35281, CA04920, CA28862, CA35128, CA35117, CA35200, CA46441, CA35176, CA12644, CA46136, CA58658, CA16385, CA46113, CA45560, CA20319, CA22433, CA35119, CA35431, CA35261, CA38926, CA32102.
PY - 1999
Y1 - 1999
N2 - Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.
AB - Purpose: To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. Patients and methods: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. Results: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. Conclusion: The observed antitumor activity of single agent menogaril against both intermediate/high- grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.
KW - Menogaril
KW - Non-Hodgkin's lymphoma
KW - Southwest Oncology Group
UR - http://www.scopus.com/inward/record.url?scp=0345440008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345440008&partnerID=8YFLogxK
U2 - 10.1023/A:1006375301205
DO - 10.1023/A:1006375301205
M3 - Article
C2 - 10638487
AN - SCOPUS:0345440008
SN - 0167-6997
VL - 17
SP - 169
EP - 172
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 2
ER -